OBJECTIVE: To examine if genetic variations in chemokine receptor and ligand genes are associated with gastric cancer risk and survival. METHODS: The study included 298 cases and 417 controls from a population-based study of gastric cancer conducted in Warsaw, Poland in 1994-1996. We investigated seven single nucleotide polymorphisms in a chemokine ligand (CXCL12) and chemokine receptor (CCR2, CCR5, CX3CR1) genes and one frameshift deletion (CCR5) in blood leukocyte DNA in relation to gastric cancer risk and survival. Genotyping was conducted at the NCI Core Genotyping Facility. Odds ratios and 95% confidence intervals were computed using univariate and multivariate logistic regression models. Survival analysis was performed using Cox proportional hazards models. RESULTS: Gastric cancer risk was not associated with single chemokine polymorphisms. A CCR5 haplotype that contained the common alleles of IVS1+151 G>T (rs2734648), IVS2+80 C>T (rs1800024) and minor allele of IVS1+246 A>G (rs1799987) was associated with a borderline significantly increased risk (OR = 1.5, 95% CI: 1.0?2.2). For gastric cancer cases, there was a greater risk of death for carriers of the minor alleles of CCR2 Ex2+241 G>A (rs1799864) (HR = 1.5, 95% CI: 1.1-2.1) and CCR5 IVS2+80 C>T (rs1800024) (HR = 1.5, 95% CI: 1.1-2.1). Carriers of the CCR5 minor allele of IVS1+151 G>T (rs2734648) had a decreased risk of death compared to homozygote carriers of the common allele (HR = 0.8, 95% CI: 0.6-1.0). CONCLUSIONS: Our findings do not support an association between gastric cancer risk and single chemokine genetic variation. The observed associations between cancer risk and a CCR5 haplotype and between survival and polymorphisms in CCR2 and CCR5 need replication in future studies.
OBJECTIVE: To examine if genetic variations in chemokine receptor and ligand genes are associated with gastric cancer risk and survival. METHODS: The study included 298 cases and 417 controls from a population-based study of gastric cancer conducted in Warsaw, Poland in 1994-1996. We investigated seven single nucleotide polymorphisms in a chemokine ligand (CXCL12) and chemokine receptor (CCR2, CCR5, CX3CR1) genes and one frameshift deletion (CCR5) in blood leukocyte DNA in relation to gastric cancer risk and survival. Genotyping was conducted at the NCI Core Genotyping Facility. Odds ratios and 95% confidence intervals were computed using univariate and multivariate logistic regression models. Survival analysis was performed using Cox proportional hazards models. RESULTS:Gastric cancer risk was not associated with single chemokine polymorphisms. A CCR5 haplotype that contained the common alleles of IVS1+151 G>T (rs2734648), IVS2+80 C>T (rs1800024) and minor allele of IVS1+246 A>G (rs1799987) was associated with a borderline significantly increased risk (OR = 1.5, 95% CI: 1.0?2.2). For gastric cancer cases, there was a greater risk of death for carriers of the minor alleles of CCR2 Ex2+241 G>A (rs1799864) (HR = 1.5, 95% CI: 1.1-2.1) and CCR5 IVS2+80 C>T (rs1800024) (HR = 1.5, 95% CI: 1.1-2.1). Carriers of the CCR5 minor allele of IVS1+151 G>T (rs2734648) had a decreased risk of death compared to homozygote carriers of the common allele (HR = 0.8, 95% CI: 0.6-1.0). CONCLUSIONS: Our findings do not support an association between gastric cancer risk and single chemokine genetic variation. The observed associations between cancer risk and a CCR5 haplotype and between survival and polymorphisms in CCR2 and CCR5 need replication in future studies.
Authors: E M El-Omar; M Carrington; W H Chow; K E McColl; J H Bream; H A Young; J Herrera; J Lissowska; C C Yuan; N Rothman; G Lanyon; M Martin; J F Fraumeni; C S Rabkin Journal: Nature Date: 2000-03-23 Impact factor: 49.962
Authors: W H Chow; M J Blaser; W J Blot; M D Gammon; T L Vaughan; H A Risch; G I Perez-Perez; J B Schoenberg; J L Stanford; H Rotterdam; A B West; J F Fraumeni Journal: Cancer Res Date: 1998-02-15 Impact factor: 12.701
Authors: W H Chow; C A Swanson; J Lissowska; F D Groves; L H Sobin; A Nasierowska-Guttmejer; J Radziszewski; J Regula; A W Hsing; S Jagannatha; W Zatonski; W J Blot Journal: Int J Cancer Date: 1999-06-11 Impact factor: 7.396
Authors: Derek Zieker; Ingmar Königsrainer; Frank Traub; Kay Nieselt; Bettina Knapp; Christian Schillinger; Christian Stirnkorb; Falko Fend; Hinnak Northoff; Susan Kupka; Björn L D M Brücher; Alfred Königsrainer Journal: Cell Physiol Biochem Date: 2008-04-24
Authors: Hendrik W van Deventer; Daniela A Palmieri; Qing Ping Wu; Everett C McCook; Jonathan S Serody Journal: J Immunol Date: 2013-03-27 Impact factor: 5.422
Authors: María Asunción García-González; David Nicolás-Pérez; Angel Lanas; Luis Bujanda; Patricia Carrera; Rafael Benito; Mark Strunk; Federico Sopeña; Santos Santolaria; Elena Piazuelo; Pilar Jiménez; Rafael Campo; Jesús Espinel; Marisa Manzano; Fernando Geijo; María Pellisé; Ferrán González-Huix; Jorge Espinós; Manuel Zaballa; Llúcia Titó; Luis Barranco; Roberto Pazo; Enrique Quintero Journal: PLoS One Date: 2012-09-28 Impact factor: 3.240